Cartesian Therapeutics, Inc.
RNACHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeCartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. At a $280.5M market cap, Cartesian Therapeutics, Inc. ranks as a micro-cap company within healthcare. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis.
Market Cap
$280.5M
Beta
0.62
P/E (TTM)
—
P/E (Fwd)
-2.43
EPS (TTM)
$-5.78
EPS (Fwd)
$-3.81
ROE
—
ROA
-17.4%
Cash
$147.6M
Total Debt
$63.9M
Free CF
-$47.5M
52W Change
-9.0%
Annual Financials
Cash vs Debt
Where RNAC stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RNAC finished 17.01% above its 150-day moving average ($7.76) and 18.54% above its 200-day moving average ($7.66). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RNAC overbought or oversold?
At the September 3, 2026 close, RNAC's RSI(14) was 54.6, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Cartesian Therapeutics, Inc. holds $147.6M in cash against $63.9M in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$47.5M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Revenue has pulled back from $110.8M (2022) to $2.8M (2025), a 97% decline worth watching.
RNAC's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Cartesian Therapeutics, Inc.'s trajectory.